Glaukos Co. (NYSE:GKOS - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $163.25.
A number of equities analysts recently weighed in on GKOS shares. Wells Fargo & Company boosted their price target on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Stifel Nicolaus boosted their target price on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Finally, Truist Financial increased their price objective on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday, December 18th.
Get Our Latest Analysis on Glaukos
Insider Buying and Selling at Glaukos
In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.
Institutional Investors Weigh In On Glaukos
A number of institutional investors and hedge funds have recently made changes to their positions in GKOS. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter worth about $43,000. Versant Capital Management Inc increased its position in shares of Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 327 shares during the last quarter. Asset Planning Inc bought a new position in shares of Glaukos in the fourth quarter worth approximately $90,000. CoreCap Advisors LLC raised its stake in Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after purchasing an additional 200 shares in the last quarter. Finally, Picton Mahoney Asset Management bought a new stake in Glaukos during the fourth quarter valued at approximately $125,000. Hedge funds and other institutional investors own 99.04% of the company's stock.
Glaukos Stock Down 4.9 %
NYSE:GKOS traded down $4.23 on Friday, hitting $81.84. The stock had a trading volume of 1,309,673 shares, compared to its average volume of 622,253. Glaukos has a 1 year low of $77.91 and a 1 year high of $163.71. The firm's fifty day simple moving average is $119.36 and its two-hundred day simple moving average is $133.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market cap of $4.63 billion, a P/E ratio of -28.51 and a beta of 0.88.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Analysts predict that Glaukos will post -1.08 earnings per share for the current year.
Glaukos Company Profile
(
Get Free ReportGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
